A5007620002- Transplantation: Methods and Outcomes
- Organ Transplantation Techniques and Outcomes
- Renal Transplantation Outcomes and Treatments
- Mesenchymal stem cell research
- Tissue Engineering and Regenerative Medicine
- Electrospun Nanofibers in Biomedical Applications
- Cardiac Fibrosis and Remodeling
- Advanced Sensor and Energy Harvesting Materials
- Atrial Fibrillation Management and Outcomes
- Conducting polymers and applications
- MicroRNA in disease regulation
- Cardiovascular Disease and Adiposity
- Cardiac electrophysiology and arrhythmias
- Pluripotent Stem Cells Research
- Cancer-related molecular mechanisms research
- Bone Tissue Engineering Materials
- Neuroscience and Neural Engineering
- Receptor Mechanisms and Signaling
- Sex and Gender in Healthcare
- Hydrogen's biological and therapeutic effects
- Mechanical Circulatory Support Devices
- Respiratory Support and Mechanisms
- Extracellular vesicles in disease
- Acute Myocardial Infarction Research
- Cardiac Arrhythmias and Treatments
California Institute for Regenerative Medicine
2021
Abstract The need to develop wearable devices for personal health monitoring, diagnostics, and therapy has inspired the production of innovative on‐demand, customizable technologies. Several these technologies enable printing raw electronic materials directly onto biological organs tissues. However, few them have been thoroughly investigated biocompatibility on cellular, tissue, organ levels or with different cell types. In addition, highly accurate multiday in vivo monitoring using such...
To expand the application of perfusion decellularization beyond isolated single organs, we used native vasculature adult and neonatal rats to systemically decellularize organs a whole animal in situ. Acellular scaffolds were generated from kidney, liver, lower limb, heart-lung system, body, demonstrating that technology is applicable any perfusable tissue, independent age. Biochemical histological analyses demonstrated organ systems (heart-lung pair limb) successfully decellularized,...
The clinical use of circulating biomarkers for primary graft dysfunction (PGD) after lung transplantation has been limited. In a prospective single-center cohort, we examined the plasma protein as indicators PGD severity and duration transplantation. study comprised 40 consecutive transplant patients who consented to blood sample collection immediately pretransplant at 6, 24, 48, 72 h transplant. An expert grader determined scored T0 (6 reperfusion), T24, T48, T72 post-reperfusion using 2016...
Processes that activate the immune system during lung transplantation can lead to primary graft dysfunction (PGD) or allograft rejection.We analyzed cytokine expression profiles after reperfusion and outcomes in a cohort of patients (n = 59) who underwent off-pump 26), with cardiopulmonary bypass (CPB; n 18), extracorporeal membrane oxygenation (ECMO; 15). Peripheral blood was collected from at baseline 6 72 h reperfusion. To adjust for clinical differences between groups, we utilized linear...
Abstract Background Sex and hormones influence immune responses to ischemia reperfusion (IR) could, therefore, cause sex-related differences in lung transplantation (LTx) outcomes. We compared men’s women’s clinical molecular post-LTx IR. Methods In 203 LTx patients, we used the 2016 International Society for Heart Lung Transplantation guidelines score primary graft dysfunction (PGD). a subgroup of 40 patients with blood samples collected before (T0) 6, 24, 48 (T48), 72 h (T72) after...
Abstract Exogenous cell-based therapy has emerged as a promising new strategy to facilitate repair of hearts damaged by acute or chronic injury. However, the field is handicapped lack standardized definitions and terminology, making comparisons across studies challenging. Even term ‘stem cell therapy’ misleading because only small percentage cells derived from adult bone marrow, peripheral blood, adipose tissue meets accepted haematopoietic developmental definition stem cells. Furthermore,...
Implantation of bone marrow-derived cells (BMCs) into mouse hearts post-myocardial infarction (MI) limits cardiac functional decline. However, clinical trials post-MI BMC therapy have yielded conflicting results. While most laboratory experiments use healthy donor mice, autologous BMCs. Post-MI BMCs are therapeutically impaired, due to inflammatory changes in composition. Thus, therapeutic efficacy the progressively worsens after MI but recovers as response resolves. The availability patient...
Close examination of the initial results cardiovascular cell therapy clinical trials indicates importance patient-specific differences on outcomes and need to optimize or customize therapies. The fields regenerative medicine have transitioned from using heterogeneous bone marrow mononuclear cells (BMMNCs) mesenchymal stromal (MSCs), which are believed elicit benefits through paracrine activity. Here, we examined MSCs BMMNCs heart failure patients enrolled in FOCUS-CCTRN trial. We sought...
Background: Sex-based differences are under-studied in cardiovascular trials as women commonly underrepresented dual sex studies, even though major sex-based epidemiology, pathophysiology, and outcomes of disease have been reported. We examined patient characteristics, outcome, BM-CD34+ frequency the ACCRUE (Meta-Analysis Cell-based CaRdiac studies) database involving patients with acute myocardial infarction (AMI) randomized to autologous cell-based or control treatment. Methods: compared...
Biocompatible Conductive Inks In article number 2107099, Cunjiang Yu and co-workers report the recent development of a conductive ink that is fully biocompatible at cell, tissue, organ levels. It also allows for conformal interfacing with human skin high-fidelity electrophysiological measurements. This cover illustrates contact film skin.
Background: Despite many cell-mediated attempts to promote myocardial repair after infarction (MI), no cell treatments are currently available. Instead, therapy clinical results remain mixed. We hypothesized that by evaluating changes in circulating cells improvers and non-improvers an MI study, we could identify associated with might be candidates for future studies. Methods: In this peripheral blood (PB) was evaluated flow cytometry at baseline days 1, 30, 90 180 bone marrow mononuclear...
Background: Although cell therapy could potentially slow or reverse progression of chronic ischemic heart failure (HF), clinical trials bone marrow-derived mononuclear cells (BM-MNC) have met with minimal success. It is unknown why some patients improve (i.e. improvers) and others do not non-improvers). B numbers, in fact, been associated improvement after acute myocardial infarction (MI). We hypothesized that improvers a higher percentage peripheral blood (PB) vs. non-improvers study...
Background: Availability of donor lungs suitable for transplant falls short current demand and results in long waiting times. More than 80% are potentially injured therefore not considered transplantation. Ex-Vivo Lung Perfusion (EVLP) offers the opportunity to objectively assess recondition organs unsuitable immediate transplant. However, biological mechanisms EVLP well understood. The objective this study was investigate Bronchoalveolar Lavage (BAL) peripheral blood (PB) inflammatory cell...
Mesenchymal stromal cells derived from bone marrow (BM-MSCs) have been considered promisingcandidates for regenerative medicine therapies more than 20 years, but to date cardiovascular clinicaltrials of MSC-based demonstrated only modest improvement. However, the mechanismsunderlying why some patients improve and others do not remain undefined. Although MSC survival aftertransplantation remains a challenge, several studies reported that BM-MSC-mediated paracrineeffects delivery exosomes may...